Minakem Minakem

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"ARCA Biopharma"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","amount":"$9.4 million","upfrontCash":"Undisclosed","newsHeadline":"ARCA Biopharma Announces $9.4 Million Registered Direct Offering","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"ARCA Biopharma"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"ARCA Biopharma"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Canbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in Singapore for Complement Dysregulation Diseases","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"VarmX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subjects Dosed in First-in-Human Trial for VarmX\u2019s Anticoagulant Reversal Agent, VMX-C001","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"VarmX"},{"orgOrder":0,"company":"Sanofi","sponsor":"Rallybio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.0 million","newsHeadline":"Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Disc medicine"},{"orgOrder":0,"company":"Garuda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$62.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fly Like an Eagle: Garuda Brings in A $62M Series B","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Garuda Therapeutics"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,240.0 million","upfrontCash":"$40.0 million","newsHeadline":"Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Scribe Therapeutics"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Product Type
            filter News Type

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              Sanofi

              Contact Supplier
              • Deals
              Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
              Contact Supplier Contact Supplier
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi

              Details:

              Rallybio plans to prosecute preclinical activities for KY1066/RLYB331 including CMC, and dose-range finding and toxicity studies, which will then support transition of the asset into clinical development.

              Lead Product(s): RLYB331

              Therapeutic Area: Hematology Product Name: KY1066

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Rallybio

              Deal Size: Undisclosed Upfront Cash: $3.0 million

              Deal Type: Licensing Agreement May 10, 2022

              Sanofi Company Banner

              12th Austrian Peptide Symposium

              Not Confirmed

              envelop Contact Supplier

              Scribe Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases

              Details:

              Under the collaboration, Sanofi receives an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies for the development of in vivo NK-cell therapies, including sickle cell disease.

              Lead Product(s): Ex-vivo NK Cell Therapy

              Therapeutic Area: Hematology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Sanofi

              Deal Size: $1,240.0 million Upfront Cash: $40.0 million

              Deal Type: Expanded Collaboration July 17, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Garuda Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Fly Like an Eagle: Garuda Brings in A $62M Series B

              Details:

              The Series B funds will funnel into two programs Blood stem cell-based therapy, slated to hit the clinic in 2024 - transfusion-dependent beta-thalassemia (TDBT) in Europe and bone marrow failure syndrome in Europe, South America and North America

              Lead Product(s): Blood Stem cell-based Therapy

              Therapeutic Area: Hematology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $62.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing February 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Disc medicine

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting

              Details:

              DISC-0998 is an investigational anti-HJV mAb with an engineered Q and L mutation (QL-mutation) in the Fc region, aimed to alter binding to the FcRn receptor, resulting in an increased PK half-life.

              Lead Product(s): DISC-0998

              Therapeutic Area: Hematology Product Name: DISC-0998

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 03, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              VarmX

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001

              Details:

              Company announced treatment of the first subjects in its first-in-human study for lead compound VMX-C001able to rapidly and effectively restore coagulation in the presence of FXa DOAC, the Trial will assess safety, tolerability, PK and PD.

              Lead Product(s): VMX-C001

              Therapeutic Area: Hematology Product Name: VMX-C001

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CANbridge Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Canbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in Singapore for Complement Dysregulation Diseases

              Details:

              CANbridge is developing CAN106, in conjunction with WuXi Biologics (2269.HK), a global company with leading open-access biologics technology platforms, as part of a strategic partnership for the development of rare disease therapeutics.

              Lead Product(s): CAN106

              Therapeutic Area: Hematology Product Name: CAN106

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: WuXi Biologics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 18, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ARCA Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201

              Details:

              The FDA provided feedback for ARCA's clinical development plans for evaluating AB201 as a potential treatment for patients with severe COVID-19.

              Lead Product(s): rNAPc2

              Therapeutic Area: Hematology Product Name: AB201

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 12, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ARCA Biopharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ARCA Biopharma Announces $9.4 Million Registered Direct Offering

              Details:

              ARCA anticipates that the net proceeds from this offering will be used to initiate its clinical trial of AB201 and for working capital and general corporate purposes.

              Lead Product(s): rNAPc2

              Therapeutic Area: Hematology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: JonesTrading Institutional Services

              Deal Size: $9.4 million Upfront Cash: Undisclosed

              Deal Type: Public Offering June 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ARCA Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy

              Details:

              AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19.

              Lead Product(s): rNAPc2

              Therapeutic Area: Hematology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Skyepharma, an Expert and Agile CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.
              SuanFarma is present in all origins: Natural, Chemical & Biotechnological.
              Post Enquiry
              POST ENQUIRY